TORONTO, Dec. 17 /CNW/ - Herbert Abramson, a director of Lorus
Therapeutics Inc. ("Lorus"), announces that he has acquired,
indirectly, through Technifund Inc., a corporation controlled by him,
553,730 common shares of Lorus at $1.03 per share. The acquisition of
the shares represents approximately 3.5% of the outstanding common
shares of Lorus. The shares were acquired pursuant to private
Upon completion of the acquisition, Mr. Abramson owns, directly or
indirectly, 6,991,541 common shares of Lorus, representing
approximately 44.6% of the issued and outstanding common shares of
Lorus. In addition, Mr. Abramson owns stock options exercisable into
14,999 common shares and warrants exercisable into 3,883,592 common
shares. If he were to exercise all of the options and warrants held by
him, Mr. Abramson would own an aggregate of 10,890,132 common shares,
representing approximately 55.6% of the then issued and outstanding
common shares of Lorus (on a partially diluted basis, i.e., assuming no
options and warrants were exercised by other holders).
The shares were acquired for investment purposes. Mr. Abramson reserves
the right to acquire further securities of Lorus depending on market
conditions and other relevant factors.
The common shares of Lorus trade on the Toronto Stock Exchange.
An early warning report in respect of the above noted transactions will
be filed on SEDAR.
SOURCE HERBERT ABRAMSON
For further information: For further information:
22 St. Clair Avenue East, 18th Floor, Toronto, ON